Illumina
ILMN
$222.29
+6.76%
Illumina is the global leader in DNA sequencing and array-based technologies, supplying instruments, consumables, and services to research, clinical, and applied markets; over 90% of revenue comes from sequencing, with a smaller microarray franchise serving consumer and agricultural screening. Its dominant installed base and consumables-driven razor-and-blade model make it the de facto standard for genomic analysis, though it faces intensifying competition from lower-cost long-read and short-read entrants. The current investor narrative centers on a sharp turnaround: after a disastrous 2024 marred by a $1.99 billion Q2 goodwill impairment tied to the GRAIL spinoff, Illumina has returned to consistent profitability, raised full-year guidance, and seen its stock roughly double over the past year. Debate now hinges on whether the post-GRAIL core business can sustain mid-single-digit growth and margin expansion, or whether the stock's massive run-up has already priced in a recovery that competitive and macroeconomic headwinds could still derail.…
ILMN
Illumina
$222.29
Related headlines
Investment Opinion: Should I buy ILMN Today?
Rating: Hold. The core thesis is that Illumina has successfully executed a turnaround from its 2024 GRAIL-related disaster, but the stock's 108% one-year rally has already priced in much of the recovery, leaving a balanced risk-reward at current levels. The analyst consensus rating of 'buy' with a mean of 2.38 and an average target price of $202.65, which sits 1.8% below the current price of $206.45, suggests limited near-term upside.
The supporting evidence is mixed but leans positive on fundamentals. Revenue grew 4.8% year-over-year in Q1 2026 to $1.091 billion, a meaningful improvement from the prior year's declines. Gross margin of 68.19% and operating margin of 21.26% are healthy for a life-science tools company, and free cash flow of $989 million TTM demonstrates strong cash generation. However, the forward PE of 33.82x is a premium to the 20-30x range of large-cap peers, and the EV/Sales of 7.07x is well above the 3-5x typical for mature tools companies. The implied upside to the analyst high target of $260 is 25.9%, but the downside to the low target of $113 is 45.3%, creating an asymmetric risk profile.
The biggest risks that could invalidate the thesis are: (1) revenue growth decelerating below 4%, which would make the premium multiple unsustainable; (2) gross margin falling below 66%, signaling competitive pricing pressure; and (3) a broader market selloff given the stock's beta of 1.467. This Hold would upgrade to Buy if the stock pulls back to the $180-190 range, where the forward PE would compress to roughly 20-21x, or if Q2 2026 earnings show revenue growth accelerating above 6% with margin expansion. It would downgrade to Sell if revenue growth stalls below 3% or if gross margins compress below 65%. Relative to its history, the PS ratio of 4.81x is near the low end of its two-year range, but relative to peers, the stock is overvalued on earnings and sales. The valuation verdict is fairly valued to slightly overvalued, with the market pricing in a successful turnaround that is not yet fully proven.
Sign up to view all
ILMN 12-Month Price Forecast
Illumina's turnaround is real, with five consecutive profitable quarters and reaccelerating revenue growth, but the stock's 108% one-year rally has already priced in much of the recovery. The forward PE of 33.82x leaves little room for disappointment, and the 130% spread in analyst targets reveals deep uncertainty about the company's trajectory. The base case of $195-215 is most likely, assuming the company meets consensus estimates of $8.96 EPS and $6.0 billion revenue. I would upgrade to bullish if Q2 2026 earnings show revenue growth accelerating above 6% with margin expansion, and downgrade to bearish if growth stalls below 3% or gross margins compress below 65%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Illumina's 12-month outlook, with a consensus price target around $202.65 and implied upside of -8.8% versus the current price.
Average Target
$202.65
0 analysts
Implied Upside
-8.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$113 - $260
Analyst target range
Illumina is covered by 20 analysts, and the consensus recommendation is "buy" with a recommendation mean of 2.38 (where 1 is strong buy and 5 is strong sell), indicating a moderately bullish but not unanimous stance. The average price target of $202.65 sits slightly below the current price of $206.45, implying a modest -1.8% downside to consensus — a notable signal that the stock has run ahead of where the average analyst sees fair value. The consensus EPS estimate of $8.96 (range $8.73–$9.24) and revenue estimate of $6.0 billion (range $5.88–$6.15 billion) suggest analysts expect roughly 10% earnings growth and mid-single-digit revenue growth, a conservative but achievable bar. The fact that the stock trades above the average target despite a "buy" rating suggests analysts have been slow to raise targets in the face of the powerful rally, or that they see limited near-term upside after the 108% one-year gain. The target range is exceptionally wide, from a low of $113.00 to a high of $260.00 — a 130% spread that signals deep disagreement about Illumina's trajectory. The high target of $260 assumes successful execution on the turnaround, multiple expansion toward 35–40x forward earnings, and possibly new catalysts such as clinical sequencing adoption or a GRAIL resolution; the low target of $113 prices in margin compression, competitive share loss, and a reversion to the pre-recovery valuation. Institutional ratings show a mixed but recently improving picture: JP Morgan upgraded to Overweight from Neutral on June 10, 2026, while Barclays maintained an Underweight and Citigroup a Sell, indicating a clear bull-bear divide. The wide dispersion and the presence of both upgrades and downgrades suggest high uncertainty, and with the stock trading above the average target, the risk-reward for new investors appears skewed to the downside unless the company delivers upside surprises in upcoming quarters.
Bulls vs Bears: ILMN Investment Factors
The bull case currently has stronger evidence: Illumina has delivered five consecutive profitable quarters, revenue growth has reaccelerated to 4.8%, and free cash flow of $989 million TTM demonstrates the core business is healthy. However, the bear case is gaining traction because the stock trades above the average analyst target of $202.65, the forward PE of 33.82x prices in a flawless turnaround, and the 130% spread in analyst targets reveals deep uncertainty. The single most important tension is whether Illumina can sustain mid-single-digit revenue growth and expand margins enough to justify its premium multiple, or whether the 108% one-year rally has already priced in a recovery that competitive and macroeconomic headwinds could still derail. If Q2 2026 earnings deliver upside and guidance is raised again, the bull case strengthens; if growth decelerates or margins compress, the stock could face a sharp multiple compression toward the 20-25x range.
Bullish
- Turnaround validated by profit recovery: After a $1.988 billion net loss in Q2 2024, Illumina has delivered five consecutive profitable quarters, including Q1 2026 net income of $134 million and EPS of $0.88. The trailing net margin of 19.59% and ROE of 31.22% confirm the core business is solidly profitable.
- Revenue growth reaccelerating: Q1 2026 revenue of $1.091 billion grew 4.8% year-over-year, a meaningful improvement from the flat-to-declining trend of the prior year. The sequential progression from $1.041 billion (Q1 2025) to $1.160 billion (Q4 2025) shows the business has found its footing.
- Strong cash generation funds itself: Free cash flow of $989 million TTM and Q1 2026 free cash flow of $251 million on just $38 million of capex demonstrate a capital-light model. The company also spent $242 million on buybacks in the quarter, returning capital to shareholders.
- Massive relative strength vs. market: ILMN is up 107.88% over the past year versus SPY's 16.22%, a relative strength advantage of 91.66 percentage points. The stock is also up 53.67% YTD, far outpacing the S&P 500's 12.08% gain.
Bearish
- Stock trades above average analyst target: The average price target of $202.65 sits below the current price of $206.45, implying -1.8% downside to consensus. This suggests the stock has run ahead of where the average analyst sees fair value, a cautionary signal after a 108% one-year gain.
- Premium valuation prices in perfection: The forward PE of 33.82x represents a 13-69% premium to large-cap medical diagnostics peers trading at 20-30x. The EV/Sales of 7.07x is well above the 3-5x typical for mature tools companies, leaving little room for disappointment.
- Extreme analyst disagreement signals uncertainty: The target range spans from $113 to $260, a 130% spread. Barclays maintains an Underweight and Citigroup a Sell, while JP Morgan is Overweight, indicating deep disagreement about Illumina's trajectory and execution risk.
- Growth remains mid-single-digit: The 4.8% revenue growth in Q1 2026 is well below the double-digit growth Illumina delivered pre-GRAIL. With sequencing at $995 million dwarfing microarrays at $96 million, the company is almost entirely levered to one product line.
ILMN Technical Analysis
Illumina is in a powerful, sustained uptrend, with the stock up 107.88% over the past year versus SPY's 16.22% — a relative strength advantage of 91.66 percentage points. At $206.45, the shares sit at roughly 83% of the 52-week range ($88.00 low to $231.81 high), a positioning that reflects strong momentum but also proximity to overhead resistance and vulnerability to profit-taking. The 25.66% maximum drawdown over the period shows the trend has not been linear, but the recovery has been decisive, with the stock now more than doubling off its lows. Short-term momentum remains constructive but is decelerating: the 1-month gain of 7.02% and 3-month gain of 28.25% are solid, yet both trail the 6-month gain of 73.57%, indicating the pace of advance is cooling. The 1-month relative strength of +8.08 points versus SPY confirms continued outperformance, but the stock's recent pullback from the August 27 high of $227.69 to $201.27 on September 10 — a 11.6% drawdown — before rebounding to $206.45 suggests buyers are defending but no longer chasing. With a beta of 1.467, Illumina is roughly 47% more volatile than the market, meaning position sizing should account for amplified swings in both directions. Key support sits at the 52-week low of $88.00, with intermediate support likely near the $190–$195 area where the stock consolidated in August; resistance is defined by the 52-week high of $231.81, and a decisive breakout above that level would signal a fresh leg higher, while a breakdown below $190 would threaten the medium-term trend and open the door to a deeper mean-reversion toward the $160s.
Beta
1.47
1.47x market volatility
Max Drawdown
-25.7%
Largest decline past year
52-Week Range
$88-$232
Price range past year
Annual Return
+120.3%
Cumulative gain past year
| Period | ILMN Return | S&P 500 |
|---|---|---|
| 1m | +16.4% | -2.4% |
| 3m | +39.7% | +2.2% |
| 6m | +75.6% | +14.8% |
| 1y | +120.3% | +14.6% |
| ytd | +65.5% | +11.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ILMN Fundamental Analysis
Illumina's revenue trajectory has stabilized and returned to modest growth after a turbulent 2024. Q1 2026 revenue of $1.091 billion grew 4.8% year-over-year, a meaningful improvement from the flat-to-declining trend of the prior year, and the sequential progression from $1.041 billion (Q1 2025) to $1.083 billion (Q3 2025) to $1.160 billion (Q4 2025) to $1.091 billion (Q1 2026) shows a business that has found its footing. Sequencing remains the overwhelming driver at $995 million, dwarfing microarrays at $96 million, so the company's growth is almost entirely levered to sequencing instrument and consumable demand. The 4.8% growth rate is respectable for a mature tools franchise but well below the double-digit growth Illumina delivered in its pre-GRAIL heyday, suggesting the investment case now rests more on margin recovery and cash generation than on top-line acceleration. Profitability has recovered emphatically from the 2024 impairment-driven losses. Q1 2026 net income was $134 million on a 12.28% net margin, with gross margin of 68.19% and operating margin of 21.26% — healthy for a life-science tools company, though the net margin is weighed down by a $75 million negative in total other income/expenses. The quarterly progression tells the story of normalization: net income swung from a $1.988 billion loss in Q2 2024 to $705 million in Q3 2024 (boosted by the impairment reversal dynamics), then settled into a sustainable $131–$334 million range across the last five quarters. Gross margin has been remarkably stable in the 66–68% band, indicating pricing power and a favorable consumables mix, while the trailing net margin of 19.59% and operating margin of 19.92% confirm the core business is solidly profitable. The balance sheet is sound but not pristine. Debt-to-equity stands at 0.94, and the current ratio of 2.08 provides ample short-term liquidity, while free cash flow of $989 million TTM and a 31.22% ROE demonstrate strong cash generation and efficient capital use. Q1 2026 free cash flow was $251 million on operating cash flow of $289 million, with capital expenditure of just $38 million — a capital-light model that funds itself internally. However, the company spent $415 million on acquisitions and $242 million on buybacks in the quarter, drawing cash down to $1.089 billion from $1.418 billion, and the 19.32 price-to-cash-flow ratio suggests the market is paying up for that cash flow. The debt-to-equity of 0.94 is manageable but not conservative, and with a cash flow-to-debt ratio of just 0.11, Illumina relies on its earnings power rather than balance-sheet strength to service obligations.
Quarterly Revenue
$1.1B
2026-03
Revenue YoY Growth
+4.8%
YoY Comparison
Gross Margin
68.2%
Latest Quarter
Free Cash Flow
$989000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ILMN Overvalued?
Because Illumina is profitable — Q1 2026 net income of $134 million and trailing EPS of $0.04 — the PE ratio is the appropriate primary metric, though the trailing PE of 24.54x is distorted by the low trailing earnings base. The forward PE of 33.82x, based on consensus EPS of $8.96, is the more meaningful figure and reveals a striking gap: the market expects earnings to grow roughly 220x from the trailing base, a reflection of the massive 2024 impairment that crushed trailing EPS. This forward multiple implies the market is pricing in a full earnings normalization, and the PEG ratio of -0.14 is meaningless given the negative trailing growth base. On a price-to-sales basis, Illumina trades at 4.81x trailing sales and 7.07x EV/Sales, while the EV/EBITDA of 15.09x is the cleanest read on the core business's valuation. Compared to the medical diagnostics and research tools sector, where large-cap peers typically trade in the 20–30x forward PE range, Illumina's 33.82x forward PE represents a premium of roughly 13–69% depending on the peer set, and its 7.07x EV/Sales is well above the 3–5x typical for mature tools companies. That premium is defensible only if Illumina delivers on the consensus EPS of $8.96 and revenue of $6.0 billion, which implies roughly 10% earnings growth off a normalized base — a reasonable but not guaranteed outcome given competitive pressures. Historically, Illumina's valuation has been extraordinarily volatile, with PE ratios ranging from negative territory during the 2022–2024 loss years to 34.32x in Q1 2026 and 15.42x in Q4 2025, and PS ratios swinging from 12.12x to 19.24x over the past two years. The current PS of 4.81x is actually near the low end of its historical band — a stark contrast to the 16.94x PS recorded in Q1 2026 historical ratios — suggesting the market has repriced the stock on normalized earnings rather than sales. The PB ratio of 7.65x is elevated versus the 5.33–8.95x range of the past two years, indicating the market is assigning a premium to book value that reflects confidence in the recovery. Net-net, the valuation is full but not egregious: the forward PE of 33.82x prices in a successful turnaround, and any disappointment on earnings or guidance would likely compress the multiple toward the 20–25x range, implying 25–40% downside risk from current levels.
PE
24.5x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 7x~161x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
15.1x
Enterprise Value Multiple
Investment Risk Disclosure
Illumina's financial and operational risks are moderate but not negligible. The debt-to-equity ratio of 0.94 is manageable but not conservative, and with a cash flow-to-debt ratio of just 0.11, the company relies on earnings power rather than balance-sheet strength to service obligations. The 4.8% revenue growth rate is respectable for a mature tools franchise but well below the double-digit growth of its pre-GRAIL heyday, and with sequencing representing $995 million of $1.091 billion in Q1 2026 revenue, the company is dangerously concentrated in a single product line. Additionally, Q1 2026 net income of $134 million was weighed down by a $75 million negative in total other income/expenses, and the 12.28% net margin, while healthy, leaves limited cushion if operating expenses rise.
Market and competitive risks are significant given the stock's premium valuation and high beta. The forward PE of 33.82x represents a 13-69% premium to large-cap medical diagnostics peers trading at 20-30x, and the EV/Sales of 7.07x is well above the 3-5x typical for mature tools companies. With a beta of 1.467, Illumina is roughly 47% more volatile than the market, meaning any macro-driven selloff would hit the stock disproportionately hard. Recent news from Zacks on August 28, 2026, noted that while fundamentals are strong, the stock's massive run-up suggests investors should wait for a pullback before adding, highlighting the risk of valuation compression. Competitive pressures from lower-cost long-read and short-read sequencing entrants could erode Illumina's dominant installed base and pricing power.
The worst-case scenario for Illumina would be a combination of decelerating revenue growth, margin compression, and multiple contraction. If Q2 2026 earnings miss expectations and management lowers guidance, the forward PE could compress from 33.82x toward the 20-25x range, implying 25-40% downside from the current price of $206.45. The 52-week low of $88.00 represents a 57.4% decline from current levels, and the analyst low target of $113.00 implies 45.3% downside. A realistic adverse scenario would see the stock retest the $160s, a level it consolidated at earlier in 2026, representing a 22-25% loss from current levels. If competitive pressures intensify and the company loses share in the clinical sequencing market, the stock could fall toward the $113 analyst low, a 45% decline.
FAQ
The key risks of holding ILMN are ranked as follows: (1) Valuation compression risk, as the forward PE of 33.82x leaves little room for disappointment and any earnings miss could trigger a sharp multiple contraction toward 20-25x, implying 25-40% downside. (2) Competitive risk, as lower-cost long-read and short-read sequencing entrants could erode Illumina's dominant installed base and pricing power, threatening the 68.19% gross margin. (3) Macro risk, as the stock's beta of 1.467 makes it 47% more volatile than the market, meaning any macro-driven selloff would hit the stock disproportionately hard. (4) Company-specific risk, as the 4.8% revenue growth is heavily dependent on sequencing, which represents $995 million of $1.091 billion in Q1 2026 revenue, leaving the company vulnerable to a slowdown in that single product line.
The 12-month forecast for ILMN includes three scenarios: a bull case with 25% probability targeting $240-260, a base case with 50% probability targeting $195-215, and a bear case with 25% probability targeting $113-160. The base case is most likely, assuming the company meets consensus estimates of $8.96 EPS and $6.0 billion revenue, with revenue growth of 4-5% and stable gross margins of 66-68%. The key assumption behind the base case is that Illumina executes on its turnaround without major competitive disruptions or macro headwinds. The bull case requires revenue growth accelerating above 6% and EPS exceeding $9.50, while the bear case would be triggered by a revenue growth deceleration below 3% or gross margin compression below 65%.
ILMN appears fairly valued to slightly overvalued relative to peers and its own history. The forward PE of 33.82x is a 13-69% premium to large-cap medical diagnostics peers trading at 20-30x, and the EV/Sales of 7.07x is well above the 3-5x typical for mature tools companies. However, the PS ratio of 4.81x is near the low end of its two-year historical range, suggesting the market has repriced the stock on normalized earnings rather than sales. The market is pricing in a successful turnaround with EPS growing to $8.96 and revenue reaching $6.0 billion, implying roughly 10% earnings growth off a normalized base. If the company delivers on these expectations, the valuation is justified; if not, the multiple could compress toward 20-25x, implying 25-40% downside.
ILMN is a good buy for investors with a moderate risk tolerance and a 12-18 month horizon who believe in the genomic sequencing growth story, but the current entry point is not ideal. The stock trades at $206.45, which is 1.8% above the average analyst target of $202.65, implying limited near-term upside. The forward PE of 33.82x is a premium to peers, and the 108% one-year rally has already priced in much of the turnaround. The biggest downside risk is a reversion to the analyst low target of $113, representing 45% downside, while the high target of $260 offers 26% upside. For those looking to initiate a position, waiting for a pullback to the $180-190 range would provide a more favorable risk-reward.
ILMN is more suitable for long-term investment than short-term trading, given its high beta of 1.467 and the 25.66% maximum drawdown over the past year. The company does not pay a dividend (dividend yield of 0%), so returns depend entirely on capital appreciation, which requires patience as the turnaround unfolds. The stock's earnings visibility is improving but still uncertain, with a 130% spread in analyst targets, making it risky for short-term traders. A suggested minimum holding period is 12-18 months to allow the company to deliver on its growth and margin expansion plans. For short-term traders, the high volatility could offer opportunities, but the risk of sharp drawdowns is significant, and position sizing should account for the stock's amplified swings.